SCHEMBL6720382

SCHEMBL6720382

Cc1noc(C)c1S(=O)(=O)Nc1cccc(C2=NCCc3cc(F)ccc32)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
NR3C2 P08235 1/20 0.45
PKM P14618 1/20 0.41
MAPK10 P53779 1/20 0.41
NR3C1 P04150 3/20 0.40
PGR P06401 3/20 0.40
LMNA P02545 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TSHR P16473 1/20 0.40
HPGD P15428 1/20 0.40
ACLY P53396 1/20 0.39
BRD4 O60885 2/20 0.39
BRD2 P25440 2/20 0.39
BRD3 Q15059 2/20 0.39
TRIM24 O15164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6720559 0.93 ALDH1A1 (0.48) ALDH1A1NR3C2PKMNR3C1PGR
SCHEMBL6720414 0.90 ALDH1A1 (0.47) ALDH1A1PKMNR3C1PGRLMNA
SCHEMBL6720489 0.89 ALDH1A1 (0.48) ALDH1A1NR3C2PKMMAPK10LMNA
SCHEMBL6718862 0.89 ALDH1A1 (0.52) ALDH1A1NR3C2NR3C1LMNAKMT2A
SCHEMBL6718857 0.84 ALDH1A1 (0.48) ALDH1A1NR3C2PKMMAPK10LMNA
SCHEMBL6716553 0.80 LMNA (0.53) MAPK10LMNAMAPT
SCHEMBL6720455 0.80 MAPK10 (0.46) MAPK10LMNAMAPTTRIM24
SCHEMBL7210296 0.79 PFKFB3 (0.56) MAPK10LMNAMAPTBRD4
SCHEMBL6718416 0.78 TRIM24 (0.45) ALDH1A1PKMMAPK10LMNAKMT2A
SCHEMBL6718228 0.78 HSD17B2 (0.45) ALDH1A1PKMMAPK10LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818651-B2 ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE ALTANA PHARMA AG (DE) 2004-11-16 US disclosed
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors ALTANA PHARMA AG (DE) 2004-03-04 US disclosed
EP-1337515-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2003-08-27 EP disclosed
WO-2002040450-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS ALTANA PHARMA AG (DE) 2002-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors PDE7B, PDE3B, PDE3A ALDH1A1 213/4885NR3C2 791/4885PKM 1869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.